Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04463017 · ClinicalTrials.gov registry record · Phase 1
Ascending Dose Study of HU6 in Healthy Volunteers
A Phase 1 study, sponsored by Rivus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT04463017 is a Phase 1 study that has completed, run by Rivus Pharmaceuticals. The registered enrollment target is 64 participants.
The verdict
NCT04463017, a Phase 1 study, has completed, sponsored by Rivus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a single ascending dose trial in healthy volunteers. The study will be conducted in up to 7 cohorts. Upon review of the safety and PK data, it may be decided to expand the current cohort versus dose escalate to the next cohort. In addition, the sponsor may elect not to enroll all 7 cohorts based on safety and/or PK and/or PD data.
Interventions
- DRUG HU6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04463017
The ClinicalTrials.gov registry entry for NCT04463017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rivus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HU6 is the first listed.
NCT04463017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04463017 about?
NCT04463017 is a clinical study titled "Ascending Dose Study of HU6 in Healthy Volunteers". This is a single ascending dose trial in healthy volunteers. The study will be conducted in up to 7 cohorts. Upon review of the safety and PK data, it may be decided to expand the current cohort versus dose escalate to the next cohort. In addition, the sponsor may elect not to enroll all 7 cohorts b...
What is the current status of trial NCT04463017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2020-08-12. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04463017?
The interventions under investigation include: HU6 (DRUG).
Who is sponsoring clinical trial NCT04463017?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.